The Indian stock market plunged over 1% for the second day in a row on Monday weighed down by US recession fears triggered risk-off sentiment.The S&P BSE Sensex plunged 2,223 points to close at 78,759 while the Nifty50 was down 668 points to close at 24,048. Market Roundup

Technical Breakout Stocks: Sun Pharma, Ajanta Pharma and JB Chemicals hit record high when Sensex falls 2,200 points - Market Roundup

On August 1, three stocks with market caps over Rs 10,000 crore appeared in the White Marubozu bullish scan, indicating a strong upward trend.

Ajanta Pharma among 2 stocks with White Marubozu Pattern

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets.

Ajanta Pharma Q1 results: PAT up 18% to Rs 246 cr on robust sales

Ajanta Pharma consolidated net profit rises 18.09% in the June 2024 quarter

Ajanta Pharma rallied 3.99% to Rs 2,524.35 after the company’s consolidated net profit jumped 18.09% to Rs 245.77 crore on 12.13% increase in revenue from operations to Rs 1144.92 crore in Q1 FY25 over Q1 FY24.

Ajanta Pharma hits record high after Q1 PAT rises 19% YoY to Rs 246 cr

Ajanta Pharma’s stock, which depreciated after marking a record high of ₹2,531.95 in May, has now formed a good base at ₹2,200

Stock to buy today: Ajanta Pharma (₹2,291.05)

The company is focusing on increasing field force productivity, adding new products and geographies

Ajanta Pharma - Investments In Branded Generics Added Certainty, Scalability, Sustainability: Dolat Capital

Growth to revive in India over the near term.

Ajanta Pharma Q3 Results Review - Asia, Africa Drive Earnings: Motilal Oswal

On a quarterly basis, JB Chemicals/Ajanta Pharma/Macleods/Sun Pharma outperformed IPM, while Mankind Pharma, Lupin underperformed.

India Pharma - IPM Growth On Moderate Uptrend In September: Motilal Oswal

Ajanta Pharma has seen market share gains across top products which should aid base business.

Pharma Key Molecule Check - Traction In Key Dr. Reddy’s, Lupin, Ajanta Pharma Products: Yes Securities

Ajanta Pharma “outperformed” the market, led by ophthalmology therapy, pain therapy, and dermatology, the brokerage said.

Ajanta Pharma Shares At All-Time High After August Sales Data

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Ajanta Pharma Limited is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.